Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Pembrolizumab in Central Nervous System Metastases From Multiple Histologies

NCT02886585 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT02886585
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02886585 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Pembrolizumab in Central Nervous System Metastases From Multiple Histologies
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 31, 2016
Completion date
June 30, 2028
Enrollment
101 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases